Most patients do not see significant weight loss or substantial glucose control improvements in the first 48 hours
KFF health tracking poll May 2024: The publics use and views of GLP-1 drugs, KFF (2024) Paragraph IV Patent Certifications, FDA.gov (2024) Oral semaglutide effectiveness and safety in real world practice
It isnt specifically approved for MC4R deficiency specifically, only for weight management and appetite control in adults and children with POMC- , PCSK1- , or LEPR- deficient obesity or those with genetically confirmed pathogenic variants, likely pathogenic variants, or variants of uncertain significance in POMC , PCSK1 , or LEPR (FDA: 2 years of age and older
A medida que la piel envejece, la degradacin del colgeno provoca lneas finas y arrugas
Week 1: Drug levels declining but still pharmacologically active
In clinical trials of semaglutide for type 2 diabetes mellitus, patients exposed to semaglutide subcutaneous injection reported increases in amylase (hyperamylasemia) and lipase, and had a mean increase from baseline in amylase of 13% and lipase of 22%
![Physiologic effects of GLP-1 (adapted from Granata et al. [11])](https://www.researchgate.net/publication/359199250/figure/fig1/AS:11431281081130351@1661532031197/Physiologic-effects-of-GLP-1-adapted-from-Granata-et-al-11.png)
